Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
Phase 2
Completed
NCT03693170
| Condition | BRAF V600E-mutant Metastatic Colorectal Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Pierre Fabre Medicament |
|---|
| Status | Completed |
|---|
| Enrollment | 95 participants |
|---|
| Interventions | encorafenib, Binimetinib, Cetuximab |
|---|
| Start date | Jan 17, 2019 |
|---|
| Completion date | Jun 29, 2020 |
|---|
| Results posted | Aug 30, 2022 |
|---|
Summary
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments
From initiation of treatment to disease progression up to a maximum of 17.6 months. · percentage of confirmed responses
| 1 Arm | 47.8 percentage of confirmed responses |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.